Hologic Announces Financial Results for Third Quarter of Fiscal 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Hologic (HOLX) PT Raised to $95 at JPMorgan
July 30, 2024 5:11 AM EDTJPMorgan analyst Casey Woodring raised the price target on Hologic (NASDAQ: HOLX) to $95.00 (from $91.00) while maintaining a Neutral rating.
The analyst comments "After the close, Hologic (HOLX) reported a F3Q24 beat, with revenues of $1.011B coming in above the Street of $1.001B and revenue dollar guidance of $992.5M-1.008B, representing+3.8% organic cc growth (vs. Street of +2.7%) and organic ex-COVID cc growth of +5.8% vs. guide of +4.0-5.6%. Moving down the P&L, adj. OPM of 31.2% came in slightly above the Street of 31.1%, with adj. EPS of $1.06 beating the Street of $1.02 and guide of... More
